Condition
Allogeneic Hematopoietic Cell Transplantation (HCT)
Total Trials
4
Recruiting
3
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 90/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
4Total
P 1 (1)
P 2 (2)
P 3 (1)
Trial Status
Recruiting3
Terminated1
Clinical Trials (4)
Showing 4 of 4 trials
NCT05088356Phase 1RecruitingPrimary
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
NCT07463651Phase 3Recruiting
MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib
NCT07304232Phase 2RecruitingPrimary
Post-transplantation Maintenance Therapy With Cidabenamide in Patients With Intermediate/High-risk AML
NCT03720392Phase 2TerminatedPrimary
Fecal Microbiota Transplantation (FMT) in Recipients After Allogeneic Hematopoietic Cell Transplantation (HCT)
Showing all 4 trials